Open AccessIron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease
Author(s) -
Tadao Akizawa,
Iain C. Macdougall,
Jeffrey S. Berns,
Hiroyasu Yamamoto,
Megumi Taguchi,
Kazuma Iekushi,
Thomas G. Bernhardt
Publication year - 2019
Publication title -
the nephron journals/nephron journals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.951
H-Index - 72
eISSN - 2235-3186
pISSN - 1660-8151
DOI - 10.1159/000502012
Subject(s) - medicine , hepcidin , transferrin saturation , kidney disease , anemia , hemodialysis , total iron binding capacity , ferritin , erythropoietin , dialysis , gastroenterology , iron deficiency , endocrinology
The current treatment for anemia associated with chronic kidney disease (CKD) includes the administration of erythropoiesis stimulating agents (ESAs) combined with iron supplementation. Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has potential to treat anemia associated with CKD through increased erythropoietin production and improved iron availability. Here, we report the effect of molidustat on iron metabolism.